Malpani K, Metcalfe S M, Hinchliffe A
Department of Surgery, General Hospital, Weston-super-Mare.
Br J Urol. 1989 Sep;64(3):257-62. doi: 10.1111/j.1464-410x.1989.tb06009.x.
The correlation between a new tumor marker, B5, and tumour behaviour in bladder cancer was recorded and an assessment made of the value of combining the B5 test with urine cytology for predicting the presence of tumour. The study group included 57 new patients, of whom 32 were B5 positive at diagnosis and were well marked by B5 on follow-up. There were no false positive shifts in new patients who became free of observable tumour, whilst 1 of 13 patients with persistent disease showed a false negative shift. When the findings from 199 cystoscopies were compared with the results of B5 and urine cytology, B5 was found to improve the prediction of recurrent tumour over cytology alone. Moreover, a high incidence of occult malignancy (7/19) was found in patients where cystoscopy had failed to show recurrence but whose combined marker results were both positive.
记录了一种新的肿瘤标志物B5与膀胱癌肿瘤行为之间的相关性,并评估了将B5检测与尿液细胞学检查相结合对预测肿瘤存在的价值。研究组包括57名新患者,其中32名在诊断时B5呈阳性,随访时B5标记良好。在无可见肿瘤的新患者中没有假阳性变化,而13名持续性疾病患者中有1名出现假阴性变化。当将199次膀胱镜检查的结果与B5和尿液细胞学检查的结果进行比较时,发现B5比单独的细胞学检查能更好地预测复发性肿瘤。此外,在膀胱镜检查未显示复发但联合标志物结果均为阳性的患者中发现了高隐匿性恶性肿瘤发生率(7/19)。